United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$233.85 USD
-2.10 (-0.89%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $233.96 +0.11 (0.05%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Brokerage Reports
0 items in cart
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 581 - 585 ( 585 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
In Response To The Tyvaso MAA Withdrawal, We Are Lowering Our Fair Value to $59 But Maintaining Our NEUTRAL Rating.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Robust Quarter - Reiterating Buy
Provider: AURIGA USA
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4 Revenues Slightly Beat Our and Consensus Estimates but GAAP EPS Missed on Higher Operating Expenses
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Although We Raised Our Q4 Estimates, Consensus Is Still Relatively High. Even So, We Believe Investors Are Focused On Better Than Expected Product Launches
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L